BR0309057A - Formulações lìquidas com baixa dosagem em entecavir e uso - Google Patents
Formulações lìquidas com baixa dosagem em entecavir e usoInfo
- Publication number
- BR0309057A BR0309057A BR0309057-4A BR0309057A BR0309057A BR 0309057 A BR0309057 A BR 0309057A BR 0309057 A BR0309057 A BR 0309057A BR 0309057 A BR0309057 A BR 0309057A
- Authority
- BR
- Brazil
- Prior art keywords
- entecavir
- liquid
- formulated
- composition
- low dosage
- Prior art date
Links
- 229960000980 entecavir Drugs 0.000 title abstract 6
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 title abstract 6
- 239000012669 liquid formulation Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 6
- 239000007788 liquid Substances 0.000 abstract 4
- 239000013543 active substance Substances 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"FORMULAçõES LìQUIDAS COM BAIXA DOSAGEM DE ENTECAVIR E USO". A presente invenção refere-se a composições farmacêuticas líquidas que têm uma dose baixa de entecavir. Em uma modalidade da presente invenção, a composição líquida de entecavir é uma composição pronta- para- uso, que é formulada para ser tanto estável como palatável. Em uma segunda modalidade da presente invenção, a composição líquida de entecavir é formulada na ocasião de ser usada, a partir de uma composição em forma de pó. As composições com baixa dosagem de entecavir também podem incluir pelo menos um componente selecionado a partir de um adoçante, conservante, agente de flavorização, agente de tamponamento ou as combinações dos mesmos. As composições líquidas do entecavir também podem ser formuladas em combinação com outros agentes farmaceuticamente ativos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37067402P | 2002-04-08 | 2002-04-08 | |
| PCT/US2003/010371 WO2003086367A1 (en) | 2002-04-08 | 2003-04-03 | Low dose liquid entecavir formulations and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0309057A true BR0309057A (pt) | 2005-02-01 |
Family
ID=29250568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0309057-4A BR0309057A (pt) | 2002-04-08 | 2003-04-03 | Formulações lìquidas com baixa dosagem em entecavir e uso |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20030190334A1 (pt) |
| EP (1) | EP1492510A4 (pt) |
| JP (1) | JP2005528389A (pt) |
| KR (1) | KR20040099403A (pt) |
| CN (1) | CN1319517C (pt) |
| AR (1) | AR039388A1 (pt) |
| AU (1) | AU2003226259A1 (pt) |
| BR (1) | BR0309057A (pt) |
| CA (1) | CA2481092A1 (pt) |
| EA (1) | EA008102B1 (pt) |
| EC (1) | ECSP045349A (pt) |
| HR (1) | HRP20040893A2 (pt) |
| MX (1) | MXPA04009735A (pt) |
| MY (1) | MY131488A (pt) |
| NO (1) | NO20044451L (pt) |
| NZ (1) | NZ535535A (pt) |
| PE (1) | PE20040324A1 (pt) |
| PL (1) | PL372322A1 (pt) |
| RS (1) | RS88404A (pt) |
| TW (1) | TWI275392B (pt) |
| WO (1) | WO2003086367A1 (pt) |
| ZA (1) | ZA200407672B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7511139B2 (en) | 2004-06-04 | 2009-03-31 | Bristol-Myers Squibb Company | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation |
| CN1732944B (zh) * | 2005-09-02 | 2013-05-08 | 海南中和药业有限公司 | 恩替卡韦分散片及其制备方法 |
| US20070060599A1 (en) * | 2005-09-09 | 2007-03-15 | Dimarco John D | Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one |
| RU2381807C1 (ru) * | 2008-07-18 | 2010-02-20 | Алексей Глебович Одинец | Противовирусное средство |
| CN101869569A (zh) * | 2009-04-21 | 2010-10-27 | 李迪 | 即用型恩替卡韦组合物 |
| EP2508172A1 (en) | 2011-04-06 | 2012-10-10 | Zentiva, a.s. | Stable and uniform formulations of entecavir and preparation method thereof |
| AP3639A (en) | 2011-08-16 | 2016-03-13 | Gilead Sciences Inc | Tenofovir alafenamide hemifumarate |
| CN102908312B (zh) * | 2011-11-10 | 2014-06-04 | 陈小花 | 抗乙肝病毒液体组合物 |
| US8517850B1 (en) * | 2012-12-11 | 2013-08-27 | Cobra Golf Incorporated | Golf club grip with device housing |
| KR101462018B1 (ko) * | 2013-04-01 | 2014-11-19 | 썬시스템즈(주) | 엔테카비르 함유 구강 붕해형 필름제제 |
| CN103301071A (zh) * | 2013-06-03 | 2013-09-18 | 北京阜康仁生物制药科技有限公司 | 一种稳定的恩替卡韦无糖型颗粒剂及其制备方法 |
| US20160175313A1 (en) * | 2013-08-06 | 2016-06-23 | Dongkook Pharmaceutical Co., Ltd., | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same |
| MY185605A (en) * | 2014-06-20 | 2021-05-25 | Ctc Bio Inc | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor |
| CN104083374A (zh) * | 2014-07-18 | 2014-10-08 | 石家庄创建医药科技有限公司 | 一种恩替卡韦口服液组合物 |
| CN109984996B (zh) * | 2018-01-02 | 2022-01-18 | 扬子江药业集团有限公司 | 恩替卡韦口服溶液及其制备方法 |
| CN108434096A (zh) * | 2018-06-20 | 2018-08-24 | 广州大光制药有限公司 | 一种恩替卡韦口服溶液及其制备方法 |
| WO2020004652A1 (ja) * | 2018-06-29 | 2020-01-02 | 学校法人同志社 | エムリカサンを含む製剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4489026A (en) * | 1982-09-07 | 1984-12-18 | The Upjohn Company | Process for preparing solid unit dosage forms of ultra-low dose drugs |
| US5206244A (en) * | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
| TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
| US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
| JP2002534438A (ja) * | 1999-01-12 | 2002-10-15 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 新規治療法 |
| CZ303395B6 (cs) * | 2000-02-29 | 2012-08-29 | Bristol-Myers Squibb Co. | Farmaceutický prostredek s nízkou dávkou entekaviru |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
-
2003
- 2003-04-02 TW TW092107553A patent/TWI275392B/zh not_active IP Right Cessation
- 2003-04-02 MY MYPI20031228A patent/MY131488A/en unknown
- 2003-04-03 WO PCT/US2003/010371 patent/WO2003086367A1/en not_active Ceased
- 2003-04-03 AU AU2003226259A patent/AU2003226259A1/en not_active Abandoned
- 2003-04-03 EA EA200401298A patent/EA008102B1/ru not_active IP Right Cessation
- 2003-04-03 BR BR0309057-4A patent/BR0309057A/pt not_active IP Right Cessation
- 2003-04-03 EP EP03746598A patent/EP1492510A4/en not_active Withdrawn
- 2003-04-03 JP JP2003583388A patent/JP2005528389A/ja active Pending
- 2003-04-03 RS YU88404A patent/RS88404A/sr unknown
- 2003-04-03 CA CA002481092A patent/CA2481092A1/en not_active Abandoned
- 2003-04-03 HR HR20040893A patent/HRP20040893A2/hr not_active Application Discontinuation
- 2003-04-03 NZ NZ535535A patent/NZ535535A/en unknown
- 2003-04-03 KR KR10-2004-7015936A patent/KR20040099403A/ko not_active Withdrawn
- 2003-04-03 PL PL03372322A patent/PL372322A1/xx unknown
- 2003-04-03 CN CNB038132877A patent/CN1319517C/zh not_active Expired - Fee Related
- 2003-04-03 MX MXPA04009735A patent/MXPA04009735A/es not_active Application Discontinuation
- 2003-04-04 US US10/407,287 patent/US20030190334A1/en not_active Abandoned
- 2003-04-07 AR ARP030101211A patent/AR039388A1/es not_active Application Discontinuation
- 2003-04-08 PE PE2003000351A patent/PE20040324A1/es not_active Application Discontinuation
-
2004
- 2004-09-22 ZA ZA200407672A patent/ZA200407672B/en unknown
- 2004-10-08 EC EC2004005349A patent/ECSP045349A/es unknown
- 2004-10-19 NO NO20044451A patent/NO20044451L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1492510A1 (en) | 2005-01-05 |
| WO2003086367A1 (en) | 2003-10-23 |
| CN1658844A (zh) | 2005-08-24 |
| AR039388A1 (es) | 2005-02-16 |
| MY131488A (en) | 2007-08-30 |
| HRP20040893A2 (en) | 2005-02-28 |
| US20030190334A1 (en) | 2003-10-09 |
| EA200401298A1 (ru) | 2005-02-24 |
| AU2003226259A1 (en) | 2003-10-27 |
| TW200306840A (en) | 2003-12-01 |
| EA008102B1 (ru) | 2007-04-27 |
| MXPA04009735A (es) | 2005-01-11 |
| RS88404A (sr) | 2006-12-15 |
| ECSP045349A (es) | 2005-01-03 |
| EP1492510A4 (en) | 2006-01-11 |
| KR20040099403A (ko) | 2004-11-26 |
| NZ535535A (en) | 2006-09-29 |
| CA2481092A1 (en) | 2003-10-23 |
| CN1319517C (zh) | 2007-06-06 |
| TWI275392B (en) | 2007-03-11 |
| ZA200407672B (en) | 2005-10-12 |
| NO20044451L (no) | 2004-11-04 |
| PL372322A1 (en) | 2005-07-11 |
| PE20040324A1 (es) | 2004-05-29 |
| JP2005528389A (ja) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0309057A (pt) | Formulações lìquidas com baixa dosagem em entecavir e uso | |
| BR0108435A (pt) | Formulação e uso de entecavir de baixa dose | |
| BRPI0414876A (pt) | compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos | |
| BR0207930A (pt) | Composições farmacêuticas lìquidas com sabor mascarado | |
| BR9907866A (pt) | Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| BR0107869A (pt) | Composições farmacêuticas eletrogiradas | |
| WO2006133941A3 (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
| BRPI0418270A (pt) | métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica | |
| AR013506A1 (es) | Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida | |
| BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR9914419A (pt) | Terapia para melhoria da percepção | |
| BR0210595A (pt) | Regime de dosagem e composição farmacêutica para contracepção de emergência | |
| WO2002034267A8 (de) | Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen | |
| BRPI0412453A (pt) | uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo | |
| BRPI0506496B8 (pt) | composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese | |
| BRPI0413474A (pt) | uso de interferon e ribavirina e kit para uso no tratamento de infecções virais | |
| UA92498C2 (ru) | Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм | |
| BRPI0410374A (pt) | composição farmacêutica que compreende valsartano | |
| BR0212744A (pt) | Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas | |
| BR0214487A (pt) | Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes | |
| EP0272393A3 (en) | Pharmaceutical combination | |
| BR0215352A (pt) | Composição farmacêutica que compreende um inibidor de alfa-glicosidase e um ácido 4-oxobutanóico, e seu uso para tratar diabetes | |
| BR0215498A (pt) | Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes | |
| PT1100463E (pt) | Novas formulacoes injectaveis contendo ramoplanina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011. |